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Sean Connolly, MD; David P. Moore, MRCPI; Janice Redmond, MD;
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Background: Most patients with Friedreich ataxia (FA)
have a GAA trinucleotide repeat expansion in intron 1
of the FA gene (FRDA) on both arms of chromosome 9.
However, some patients are compound heterozygotes and
harbor a GAA expansion on one allele and a point mu-
tation on the other. Compound heterozygous patients with
FA who have a GAA expansion and a G130V mutation
have been reported to have an atypical phenotype with
a slow disease progression, minimal or no ataxia, or gait
spasticity.
Objective: To describe intrafamilial phenotypic vari-
ability in a GAA expansion/G130V mutation compound
heterozygous family with FA.
Setting: Tertiary referral university hospital setting.
Patients and Methods: A 34-year-old man pre-
sented to our hospital with a 24-year history of stiff legs
and mild unsteadiness of gait. Clinical examination
showed a spastic paraparesis with normal to pathologi-
cally brisk deep tendon reflexes and mild left upper limb
ataxia. His 27-year-old sister presented with a slowly pro-
gressive early-onset ataxic syndrome. She had ataxia of
gait, mild to severe limb ataxia, and reduced or absent
deep tendon reflexes, but no evidence of spasticity on
examination.
Results: Neurophysiologic investigations showed evi-
dence of a sensory axonal neuropathy, and molecular ge-
netic analysis showed that both siblings were com-
pound heterozygotes with a GAA expansion and a G130V
mutation.
Conclusions: This report confirms that compound het-
erozygous patients with FA who have a GAA expansion
and a G130V mutation may present with an ataxic phe-
notype and that intrafamilial phenotypic variability in
these pedigrees can occur. It also emphasizes the impor-
tance of performing molecular genetic analysis for the
GAA trinucleotide expansion in patients presenting with
a spastic paraparesis of undetermined etiology, espe-
cially when there is neurophysiologic evidence of a sen-
sory axonal neuropathy.
Arch Neurol. 2002;59:296-300
F RIEDREICH ATAXIA (FA) is aprogressive neurodegenera-tive disorder with a preva-lence of approximately 1 in50000 in European popula-
tions.1 According to Harding’s manda-
tory clinical diagnostic criteria for FA, af-
fected individuals should have an age at
onset younger than 25 years and defi-
nitely younger than 27 years, ataxia of gait,
ataxia of all 4 limbs, lower limb areflexia,
and a mode of inheritance consistent with
an autosomal recessive disorder.2,3 Dys-
arthria was present in all patients with a
disease duration of at least 10 years, and
96% of patients had neurophysiologic
evidence of a sensory axonal neuropathy
in Harding’s original series.2 The major-
ity of patients with FA, including some
individuals with an atypical phenotype,
have a GAA trinucleotide repeat expan-
sion in intron 1 of the FA gene (FRDA) on
both arms of chromosome 9q 13-21.1.1,3-5
Normal alleles contain between 6 and 34
GAA repeats, whereas FA alleles carry be-
tween 66 and 1700 repeats.1,3,4,6,7 Some in-
dividuals are compound heterozygotes with
a GAA trinucleotide repeat expansion on
one allele and a point mutation on the
other,3,4,7-12 and Bidichandani and col-
leagues8 identified one such missense mu-
tation, the G130V mutation, in exon 4 of
the FRDA gene in 1997. Although the phe-
notype may vary between family mem-
bers harboring 2 GAA expansions,3,13 in-
trafamilial phenotypic variability has rarely
been described in compound heterozy-
gous FA pedigrees with a GAA expansion
on one allele and a G130V mutation on the
other.8,9
OBSERVATION
Author affiliations are listed
at the end of this article.
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REPORT OF CASES
CASE 1
A 34-year-old right-handed man (subject III:1; Figure,
A) presented to our hospital with a 24-year history of stiff
legs and unsteadiness while walking; his clinical history
has been briefly alluded to previously.3 He was the off-
spring of two unrelated Irish parents who had no symp-
toms of ataxia or neurologic disease.
He had been well until 10 years of age, when he
developed a febrile illness with vomiting, nocturnal
confusion, agitation, and arthralgia during a 3-week
period. He was treated with a course of oral amoxicillin,
and although his symptoms improved within weeks, he
complained of lower limb aching pains for the follow-
ing 2 months. Subsequently, he noted stiffness in both
legs and incoordination of the left more than right leg,
with difficulty correcting his posture if pushed over. He
had no subjective limb weakness, sensory symptoms, or
sphincter disturbance. The unsteadiness while walking
gradually increased, so that he required assistance to
walk within 6 years and began using crutches 10 years
after symptom onset. Although his leg stiffness subjec-
tively increased during the 5-year period before the cur-
rent examination, he was still ambulatory with the aid
of 2 crutches. He had no cardiac symptoms and no
history of diabetes and was not taking any medication
at the time of assessment. One of his sisters had been
given a clinical diagnosis of FA at 20 years of age (pa-
tient III:2), but there was no other family history of
ataxia.
General physical examination disclosed a very mild
thoracic scoliosis, fixed flexion contractures at the left
knee and hip joints, and pes planus, but was otherwise
normal. The findings on neurologic examination are out-
lined in the Table; the patient had a spastic paraparesis
with normal to pathologically brisk reflexes through-
out, bilateral extensor plantar responses, and minimal
ataxia. He did not fulfill all of Harding’s mandatory clini-
cal diagnostic criteria for FA, and he did not have dys-
arthria 24 years after disease onset.
Results of routine hematologic and biochemical in-
vestigations were normal, as were levels of blood glu-
cose, vitamin E, vitamin B12, and folate. Thyroid func-
tion test results, autoantibody screening results, and
treponemal serologic findings were normal or negative.
His electrocardiogram was generally of low amplitude and
showed p mitrale, but was otherwise normal, and a 2-di-
mensional transthoracic echocardiogram was normal.
Magnetic resonance images of the brain were normal, but
magnetic resonance images of the cervical spine showed
a right-sided posterior disc protrusion at C4-5, posteri-
orly displacing the cord at this level, but without evi-
dence of signal abnormality within the cord.
CASE 2
The sister (subject III:2; Figure, A) of subject III:1 was
assessed at 27 years of age. She had had normal devel-
opmental milestones, but had transient ataxia and vom-
iting for a few days associated with a febrile illness at 5
years of age. Ten years later, she developed a sore throat,
arthralgia, and fever and was diagnosed as having rheu-
matic fever. Subsequent to this illness, she had mild per-
sistent left leg weakness and mild ataxia of gait, but was
able to run and continued to play sports. The ataxia of
gait increased slowly until 19 years of age, and after a re-
currence of rheumatic fever at 20 years of age, she was
clinically diagnosed as having FA. Her unsteadiness while
walking increased during the 7-year period before pre-
sentation, but she was still able to walk without assis-
tance at the time of assessment.
General physical examination showed a mild tho-
racic scoliosis and left pes cavus, but was otherwise nor-
mal. Her neurologic findings are outlined in the Table.
In contrast to her clinically affected brother (subject III:
1), she had no evidence of spasticity or limb weakness,
and she had reduced or absent deep tendon reflexes and
more pronounced ataxia of gait and limbs. It was of in-
terest that she did not have dysarthria at least 12 years
after disease onset either.
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A, Family tree of the compound heterozygous patients with Friedreich ataxia
(subjects III:1 and III:2). Squares indicate males; circles, females; horizontal
line above symbols, examined family members; diagonal slash, deceased;
shading, G130V mutation; solid sections, GAA expansion; and arrow, index
case with the G130V mutation. Some unaffected family members are
represented as triangles to preserve anonymity. Asterisk indicates GAA
repeat number within normal range and G130V point mutation testing
negative. B, The 2.5% agarose gel showing polymerase chain reaction
amplification products from the G130V mutation analysis of the pedigree.
M indicates 100–base pair (bp) ladder showing 3 size markers of 100, 200,
and 300 bp. The positions of the 104-bp and 77-bp fragments are indicated
on the right.
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Results of routine hematologic and biochemical in-
vestigations were normal, and levels of blood glucose, vi-
tamin B12, and folate and treponemal serologic findings
were normal or negative. Vitamin E levels were mildly
reduced at 10.7 µmol/L (reference range, 11.5-35 µmol/L).
An electrocardiogram showed T-wave inversion in leads
III and V1, but no other signs of cardiomyopathy. Two-
dimensional transthoracic echocardiography at age 23
years had shown concentric left ventricular hypertro-
phy with good left ventricular function.
MOLECULAR GENETIC ANALYSIS
In view of the clinical diagnosis of FA in subject III:2,
polymerase chain reaction (PCR) analysis for the GAA
trinucleotide repeat expansion was performed by means
of established techniques.3,5,14 Subject III:1 was estimated
to have approximately 954 GAA repeats and subject III:2
was estimated to have 917 GAA repeats on one allele of
chromosome 9, but the GAA repeat number on the
other allele was normal in both subjects. The diffuse
PCR product associated with the GAA expansion in sub-
ject III:2 overlapped the expansion in subject III:1 on
agarose gel electrophoresis (data not shown). Because
both patients were presumed to be compound heterozy-
gotes, G130V point mutation testing was performed
with the following primers: FRDA G130Vf: 5-AAG-
CAATGATGACAAAGTGCTAAC; FRDA G130Vr:
5-CTCCACCCAGTTTGACAGTTAAGTCA. The 25-µL
reaction contained 200 ng of DNA, 100 ng of each
primer, 200µM deoxynucleotide mixture (dNTP), and
standard PCR buffer containing 1.5mM magnesium
chloride and 1 U of Taq polymerase (Gibco BRL, Life
Technologies, Paisley, Scotland). The PCR conditions
were 94°C for 5 minutes; followed by 35 cycles of 30
seconds at 94°C, 59°C, and 72°C, respectively, and a
final extension at 72°C for 5 minutes. The underlined T
in the FRDA G130Vr primer results in the generation of
a HincII site in the presence of the G130V mutation.
After PCR, 10 µL of the PCR product was digested for a
minimum of 2 hours with 10 U of HincII (New England
Biolabs Inc, Beverly, Mass) with the use of conditions
recommended by the manufacturer. The digestion prod-
ucts were visualized on a 2.5% agarose gel containing
ethidium bromide, 0.5 µg/µL (Figure, B). Wild-type
sequences from subjects not carrying the G130V muta-
tion result in an uncut PCR product of 104 base pairs
(bp). The G130V mutation results in 2 additional prod-
ucts of 77 and 27 bp, but the 27-bp product is generally
not visible on the agarose gel. This analysis showed a
G130V mutation within exon 4 of the FRDA gene in
both patients (subjects III:1 and III:2). Subsequent
screening of the unaffected parents confirmed that the
father (subject II:1) was a carrier of the GAA expansion
and the mother (subject II:2) carried the G130V muta-
tion. The remaining sibling (subject III:3) was pheno-
typically and genotypically normal.
COMMENT
The first family reported to be heterozygous for the GAA
trinucleotide repeat expansion and a G130V mutation
exhibited an atypical FA phenotype.8 Although the clini-
cal details of the 3 affected members were not published
in detail, the 2 older siblings presented with leg weak-
ness in the early teens, with a gradual disease progres-
Clinical Characteristics of the 2 Affected Patients
Clinical Details Subject III:1 Subject III:2
Age at examination, y 34 27
Disease duration, y 24 12†
Gait Spastic scissoring Ataxic
Titubation No Mild
OA/SP* Right SP No
Nystagmus Very mild horizontal gaze–evoked No; jerky pursuit movements
Dysarthria No No
Upper limb tone Normal Normal
Lower limb tone Severe spasticity Normal
Pyramidal weakness Not in arms/severe in legs No
Upper limb reflexes ++ to +++ Absent
Lower limb reflexes ++++ Right and left knee jerks,
+++ left ankle jerk/++ right ankle jerk
+ Right knee jerk (reinforced),
absent left knee/ankle jerks
Extensor plantar response Bilateral Bilateral
Upper limb ataxia Mild left Mild right and left
Lower limb ataxia Indeterminate; spasticity Severe right and left
Cerebellar rebound Bilateral Bilateral
Sensation in upper limbs Impaired vibration Normal
Sensation in lower limbs Impaired pinprick, temperature, vibration Impaired vibration and joint position
Distal amyotrophy Legs No
Pes cavus No; pes planus Left and varus deformity
Nerve conduction studies Sensory axonal neuropathy Sensory axonal neuropathy
*OA indicates optic atrophy; SP, suspicious pallor of the optic disc; +, reduced deep tendon reflex; ++, normal deep tendon reflex; +++, brisk deep tendon reflex;
and ++++, brisk deep tendon reflex with clonus. Subject III:2 was considered to have had an age at onset of the disease at 15 years because of the presence of
persistent symptoms after this age.
†Subject III:2 was considered to have onset at age 15 years because of the presence of persistent symptoms after this age.
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sion so that they were able to walk with assistance at least
20 years after disease onset. They did not have dysar-
thria, they had minimal or no ataxia, and their deep ten-
don reflexes were either reduced or absent. The authors
reported “little intrafamilial phenotypic variation.” A sub-
sequent collaborative study of the phenotypic expres-
sion of compound heterozygous patients with FA in-
cluded 6 patients from 3 families who were compound
heterozygotes with a GAA expansion and a G130V mu-
tation.9 Four of these 6 patients had a more spastic than
ataxic gait. There was some intrafamilial phenotypic vari-
ability in one family with 2 affected siblings, in which
one sibling had mild gait ataxia, retained upper limb re-
flexes, and brisk knee jerks, whereas the other had a spas-
tic gait without ataxia, retained upper limb reflexes, and
absent lower limb reflexes. Ataxia of the limbs was not
commented on in that article. Two recent reviews have
emphasized that compound heterozygotes harboring a
GAA expansion and a G130V mutation all have an atypi-
cal FA phenotype, but they stated that all patients have
brisk knee reflexes7 or a spastic gait.15
We report an additional compound heterozygous FA
family with a GAA trinucleotide repeat expansion on one
allele and a G130V mutation on the other allele of chro-
mosome 9. This is the second report of a G130V muta-
tion in a family of Irish descent with FA, and all cases
described to date are of European origin (Irish, English,
or French).16 Although the difference in disease dura-
tion between the 2 affected siblings may have influ-
enced the clinical findings, there was definite intrafamil-
ial phenotypic variability in this family, with a more spastic
than ataxic phenotype in the brother (subject III:1) and
a more ataxic phenotype, without limb spasticity, in the
sister (subject III:2). The presence of cervical cord com-
pression on magnetic resonance imaging may have con-
tributed to the spastic paraparesis in subject III:1, but this
finding would not account for the preservation of deep
tendon reflexes that are typically absent in the lower limbs
in FA. If the phenotype had been consistent within the
family, one would have expected lower limb hypore-
flexia or areflexia in subject III:1 at 24 years after disease
onset, in view of these findings in his younger sibling ear-
lier in her disease course. Conversely, one cannot com-
pletely exclude the possibility that borderline vitamin E
deficiency contributed to a more pronounced ataxic phe-
notype with hyporeflexia or areflexia in subject III:2.17
This patient is unavailable for follow-up, so we cannot
comment on whether her clinical condition has stabi-
lized with vitamin E replacement therapy. However, be-
cause the size of the GAA trinucleotide repeat expan-
sion in peripheral blood lymphocytes was comparable in
the 2 affected siblings, the variation in phenotype is most
likely to be secondary to somatic mosaicism in the size
of the GAA expansion.18 The influence of other modi-
fier genes cannot be excluded.
The GAA trinucleotide repeat expansion is believed
to interfere with messenger RNA transcription in the FRDA
gene,4,8,19 thus leading to reduced levels of functional
frataxin protein in affected individuals. The extent of re-
duction in the levels of frataxin appears to be inversely pro-
portional to the size of the expansion.9 It has been pro-
posed that the G130V mutation leads to the production
of an abnormal frataxin protein with modified or re-
duced function.9 The resulting combination of “frataxin
deficiency,” caused by a GAA expansion, and “frataxin dys-
function,” secondary to a G130V mutation, may account
for the difference in phenotypic expression between pa-
tients with FA who are compound heterozygotes with a
GAA expansion and a G130V mutation and those with 2
GAA expansions. In addition, the degree of frataxin dys-
function may vary depending on the point mutation pre-
sent in the FRDA gene. It has been postulated that the
G130V mutation causes more subtle loss of frataxin func-
tion than another missense mutation (I154F) that is as-
sociated with a typical FA phenotype.8
Although compound heterozygotes with FA who
have a GAA expansion and a G130V mutation com-
monly present with a predominantly spastic phenotype,
this report confirms that these patients may present with
an ataxic phenotype instead, with reduced or absent deep
tendon reflexes. In addition, intrafamilial phenotypic vari-
ability in these pedigrees may occur. It also emphasizes
the importance of performing molecular genetic analy-
sis for the GAA trinucleotide repeat expansion in pa-
tients presenting with a spastic paraparesis of undeter-
mined etiology, especially when there is neurophysiologic
evidence of sensory axonal neuropathy that is typically
seen in FA.
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